Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
reduction decrease » reduction decreased (Expand Search), reduction reuse (Expand Search), production increases (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
reduction decrease » reduction decreased (Expand Search), reduction reuse (Expand Search), production increases (Expand Search)
-
721
-
722
-
723
-
724
-
725
Summary of the screened symptoms at baseline (t0) for completers (n = 160).
Published 2025Subjects: -
726
-
727
Changes in continuous sleep measures from pre (t1) to post (t2) intervention.
Published 2025Subjects: -
728
-
729
Sociodemographic information, participant flow, engagement, and compliance.
Published 2025Subjects: -
730
Changes in mental health symptoms after the sleep intervention (n = 160 completers).
Published 2025Subjects: -
731
-
732
Density differences between pre- and post-measurements for program completers (N = 160).
Published 2025Subjects: -
733
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…(B, C) Summarized bar graph showed EVO significantly decreased calcium deposition and calcium content in CER treated P<sub>i</sub>-induced VSMCs. …”
-
734
-
735
-
736
Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
737
Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx
Published 2025“…Avoiding prolonged dosing cycles and refraining from using AGs in patients with the m.1555 A > G gene variant can significantly mitigate the risk of ototoxicity. Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.…”
-
738
-
739
-
740